Published OnlineFirst June 16, 2017; DOI: 10.1158/0008-5472.CAN-16-1627

Therapeutics, Targets, and Chemical Biology

Cancer Research

A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220

Panpan Hou[1,2], Chao Wu[2], Yuchen Wang[2,3], Rui Qi[2], Dheeraj Bhavanasi[4], Zhixiang Zuo[5], Cedric Dos Santos[6], Shuliang Chen[7], Yu Chen[1], Hong Zheng[8], Hong Wang[9], Alexander Perl[4], Deyin Guo[1], and Jian Huang[2]

Abstract

Acute myeloid leukemia (AML) is a malignant hematopoietic disease and the most common type of acute leukemia in adults. The mechanisms underlying drug resistance in AML are poorly understood. Activating mutations in FMS-like tyrosine kinase 3 (FLT3) are the most common molecular abnormality in AML. Quizartinib (AC220) is a potent and selective second-generation inhibitor of FLT3. It is in clinical trials for the treatment of relapsed or refractory FLT3-ITD–positive and –negative AML patients and as maintenance therapy. To understand the mechanisms of drug resistance to AC220, we undertook an unbiased approach with a novel CRISPR-pooled library to screen new genes whose loss of function confers resistance to AC220. We identified SPRY3, an intracellular inhibitor of FGF signaling, and GSK3, a canonical Wnt signaling antagonist, and demonstrated reactivation of downstream FGF/Ras/ERK and Wnt signaling as major mechanisms of resistance to AC220. We confirmed these findings in primary AML patient samples. Expression of *SPRY3* and *GSK3A* was dramatically reduced in AC220-resistant AML samples, and SPRY3-deleted primary AML cells were resistant to AC220. Intriguingly, expression of *SPRY3* was greatly reduced in *GSK3* knockout AML cells, which positioned SPRY3 downstream of GSK3 in the resistance pathway. Taken together, our study identified novel genes whose loss of function conferred resistance to a selective FLT3 inhibitor, providing new insight into signaling pathways that contribute to acquired resistance in AML. *Cancer Res; 77(16); 4402–13. ©2017 AACR.*

Introduction

Acute myeloid leukemia (AML) is a progressive malignant disease of the bone marrow and blood. FMS-like tyrosine kinase 3 (FLT3) is a protein kinase receptor that is expressed on the surface of many hematopoietic progenitor cells. *FLT3* gene is one of the most frequently mutated genes in AML (1–3). Internal tandem duplication (ITD) of the *FLT3* gene is a gain-of-function mutation common in AML. It is associated with worse prognosis and adverse disease outcome (4–7). Mechanistically, *FLT3-ITD* mutations result in loss of the autoinhibitory function and subsequent constitutive activation of FLT3 kinase as well as its downstream proliferative signaling pathways, including the Ras/MAPK/ERK, STAT5, and PI3K/Akt/mTOR pathways (8–10). Clinically, *FLT3-ITD* mutations are present in roughly 20% of adult AML cases. In majority of the cases, it is a *de novo* mutation with patients presenting a high leukocyte count with normal cytogenetics. Numerous clinical trial studies have established that patients with *FLT3-ITD* are far more likely to relapse and do so more rapidly than their *FLT3* wild-type counterparts. The median survival of *FLT3*-mutant AML patients after first relapse has been reported to be <5 months (11–13).

The poor prognosis of patients harboring *FLT3* mutations renders FLT3 as an obvious target of therapy. A number of small-molecule tyrosine kinase inhibitors (TKI) with activity against FLT3 have now been identified and some are currently in clinical trials (12, 14, 15). Quizartinib (AC220) is a once-daily, orally administered, potent, and selective second-generation inhibitor of FLT3. It is currently under clinical trials for the treatment of relapsed or refractory *FLT3-ITD*–positive and –negative AML patients and as a maintenance therapy. Importantly, even though no FLT3 inhibitors are approved for clinical use, several resistant mechanisms of FLT3 inhibitors have been reported through the early clinical studies (16, 17).

Sprouty proteins were first identified in *Drosophila* by genetic screens as modulators of tracheal and eye development. Several initial elegant studies have demonstrated that *Drosophila* Sprouty inhibits receptor tyrosine kinases (RTK)-mediated Ras signaling. Later, studies in mammalian systems also revealed crucial roles for

[1]State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, P.R. China. [2]Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania. [3]Department of Physiology and Pathophysiology, School of Basic Medical Science, Peking University, Beijing, P.R. China. [4]Department of Medicine (Hematology-Oncology), University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. [5]Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, P.R. China. [6]Clinical Biomarkers - Oncology at AMGEN, Inc., South San Francisco, California. [7]School of Basic Medical Sciences, Wuhan University, Wuhan, P.R. China. [8]Division of Hematology/Oncology, Penn State Hershey Cancer Institute, Penn State University College of Medicine, Hershey, Pennsylvania. [9]Center for Metabolic Disease Research, Department of Pharmacology, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

P. Hou and C. Wu contributed equally to this article.

Corresponding Author: J. Huang, Temple University Lewis Katz School of Medicine, 3500 N. Broad Street, MERB 845B, Philadelphia, PA 19140. Phone: 215-707-2647; Fax: 215-707-5255; E-mail: jianh@temple.edu

doi: 10.1158/0008-5472.CAN-16-1627

Published OnlineFirst June 16, 2017; DOI: 10.1158/0008-5472.CAN-16-1627

Sprouty in various developmental and physiological processes as well as cancer development, progression, and metastasis (18–20). There are four members in the mammalian Sprouty family, *SPRY1-4*. Previous studies implicated Sprouty 1, 2, and 4 in stem cell maintenance, development, and cancers (21–23). However, very little is known about *SPRY3*.

Glycogen synthase kinase 3 (GSK3) is a serine/threonine protein kinase first identified as the kinase that phosphorylates and inhibits glycogen synthase. It was later discovered to regulate multiple substrates and is implicated in many cellular processes including embryo development, cell-cycle regulation, cell proliferation, and differentiation (24, 25). The mammalian GSK3 is encoded by two known genes, *GSK3A* and *GSK3B*. GSK3 is a negative regulator of several other signaling pathways, including Wnt, Notch, and PI3K/Akt/mTOR signaling; inhibition of GSK3 by inhibitors activates these pathways (24–26).

Although great success has been achieved in the last three decades in AML therapy, one major obstacle in the treatment of leukemia is drug resistance (27, 28). Studies on the mechanisms of AML drug resistance will yield important information about the signaling pathways of leukemia pathogenesis as well as how to circumvent this resistance and improve efficacy of anti-AML drugs (29, 30). Here, we reported a genome-wide CRISPR screen for mutations that confer resistance to a selective FLT3 inhibitor AC220. We found that loss-of-function mutations in *SPRY3* and *GSK3* cause resistance to AC220 in AML cells and that reactivation of downstream signaling in the Wnt and Ras/MAPK pathways is the major mechanism of AC220 resistance conferred by *GSK3* and *SPRY3* deletions.

Materials and Methods

CRISPR screen and sgRNAs construction

GeCKO library was purchased from Addgene (#1000000048), amplified, and packaged as lentivirus based on the instructions on Addgene website. The loss-of-function screen was carried out as described (31). MV4-11 cells were transduced with lentivirus carrying GeCKO library, and puromycin selection was performed for 2 days. Then we treated transduced MV4-11 cells with AC220 for 14 days and the survived cells were harvested. The genomic DNA was extracted and PCR was carried out before deep sequencing of sgRNA sequence in the survived cells genome. All deep sequencing data are available at GEO (series accession number GSE 98612). For data analysis, we calculated the enrichment score as: The enrichment score = (sgRNA number from the reads)/(sgRNA number in the library) X $\log_2$ (average abundance). The sgRNAs used for validations were synthesized and constructed as described (31). Primer sequences are shown in Supplementary Table S3.

Cell lines and patient samples

Ba/F3-ITD and Ba/F3 lines were a kind gift from Drs. James D. Griffin and Ellen Weisberg at Dana Farber Cancer Institute (Boston, MA) and Dr. Stephen Sykes at Fox Chase Cancer Center (Philadelphia, PA) in 2015. MV4-11 line was kindly provided by Dr. Martin Carroll at the University of Pennsylvania (Philadelphia, PA) in 2014. MV4-11 cells were maintained in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. The IL3-dependent murine pro-B cell line Ba/F3 was cultured in RPMI 1640 supplemented 10% FBS and 10 ng/ml IL3 and 1% penicillin/streptomycin. All cell lines were analyzed and authenticated by morphologic inspection and biochemical examination of the *FLT3-ITD* pathway as well as short tandem repeat profiling analysis. Mycoplasma testing was also performed to exclude the possibility of mycoplasma contamination of all cell lines. The frozen patient samples were obtained from Xenograft core facility of the University of Pennsylvania, and written informed consent was obtained from the patients, the studies were conducted in accordance with recognized ethical guidelines, and that the studies were approved by the University of Pennsylvania and Temple review board. For culturing primary AML cells, cells were thawed quickly and resuspended in 10 mL cold RPMI 1640 with 2% HI FBS and centrifuged at 2,000 rpm for 5 minutes. Cells were incubated for 4 hours and filtered with 40μm filter, then resuspended in 12 mL RPMI 1640 supplemented with 2% HI FBS, and plated in a 6-well plate.

Lentiviral packaging and transduction

Lentivirus was packaged as previously described (32). For transduction, 0.5 million MV4-11 cells were seeded in 12-well plate coated with 8 μg/mL polybrene (Sigma-Aldrich) and transduced with the lentivirus at a multiplicity of infection (MOI) of 0.3 or 20, and then the cells were centrifuged at 1,200 *g* for 2 hours at room temperature and cultured for another 2 hours in the incubator. After 2 hours, medium was changed (RPMI 1640 supplemented with 10% FBS).

Primary AML cells transfection

For patient primary cells, the cells were prestimulated with cytokines for 36 hours and nucleotransfected with the P3 Primary Cell 4D-Nucleofector X Kit (V4XP-3012) in antibiotics-free medium after prestimulation. In brief, 2×10^6 primary cells per sample were washed twice in PBS and resuspended in 100 μL nucleofector solution with 4 μg of plasmids accordingly. The cell/DNA mixture was transferred into the cuvette and transfected with Lonza 4D-Nucleofector System. After transfection, the cells were cultured in RPMI 1640 medium supplemented with 2% HI FBS. After 24 hours, medium was changed with the complete primary cell culture medium and cultured for another 24 hours.

T7EN1 assays and DNA sequencing

After genomic DNA extraction, the genomic region flanking the sgRNA target site was amplified by PCR and T7EN1 assay was performed. T7EN1 assay was conducted as described in our previous work (32). To identify the mutations, the PCR product was sequenced by Sanger sequencing. The primers used for Sanger sequencing were listed in Supplementary Table S3.

Generation of mutant single clones

About 2,000 transduced MV4-11 cells were mixed with 1 mL of methylcellulose (MethoCult H4034 Optimum, Stem Cell Technologies) in a 6-well cell culture plate and cultured at 37°C in a 5% CO_2 incubator. Two weeks later, single-clone colonies were picked and cultured in 96-well plate with the complete medium supplemented with 2% penicillin/streptomycin. The cells were passaged every 2 or 3 days, and one-third of cells was collected for genomic DNA extraction. Then *SPRY3* target region was PCR amplified and sequenced.

Cell number measurement

Cells (0.4×10^6) were seeded with 1 mL complete medium in 12-well plate and AC220 was added at the indicated amounts

Published OnlineFirst June 16, 2017; DOI: 10.1158/0008-5472.CAN-16-1627

to cells. After 3, 6, or 8 days, 100 μL cell suspension was transferred to a 96-well plate and 10 μL CCK-8 solution (DOJINDO) was added in each well. The mixture was incubated for 3 hours in incubator. The absorbance at 450 nm was measured using a microplate reader. Cell number was calculated based on the growth standard curve.

Off-target effect examination

Off-target sites were predicted using an online search tool (http://crispr.mit.edu). Note that 3 bp mismatches compared with the target consensus sequence were allowed. The predicted off-target sequences were searched using UCSC browser, and 500 bp flanking sites were PCR amplified in primary cells and single-mutation clone. The PCR product was subjected to T7EN1 assay to determine the mutation. The PCR product was cloned into a TA vector and Sanger sequenced to identify mutations.

Immunoblot analysis

Immunoblotting was performed using whole-cell lysates of MV4-11and Ba/F3 cells supplemented with protease and phosphatase inhibitors (Roche). Proteins were separated by SDS-PAGE, transferred onto polyvinylidene difluoride membranes (Merck Millipore), and incubated with primary antibodies listed in Supplementary Table S4. Bands were visualized using horseradish peroxidase–conjugated secondary mouse (Promega) or rabbit (Sigma) or sheep (R&D Systems) antibodies, and quantifications were performed using the MultiGauge software (Fujifilm).

Results

Loss-of-function CRISPR screen in AML cells identified genes critical for drug resistance to AC220

To identify genes whose loss of function confers drug resistance to the FLT3 inhibitor AC220, we performed a genome-wide CRISPR genetic screen in MV4-11, a human AML line harboring a *FLT3-ITD* mutation. This line was established from blast cells of a 10-year-old male with biphenotypic B-myelomonocytic leukemia. It has been shown to be a *FLT3*-mutant cell line expressing the phosphorylated receptor protein, making it an appropriate model for *FLT3-ITD*--related research (33). For CRISPR screening, we transduced MV4-11 cells with lentivirus containing a pooled genome-scale CRISPR-Cas9 knockout (GeCKO) library, targeting 18,080 human genes with 64,751 unique guide sequences (6 sgRNAs per gene; ref. 31). This library has been demonstrated to be a very efficient tool to screen for mutations that confer resistance to a BRAF inhibitor in a melanoma line. It is considered superior to an shRNA library because of its ability to knock out genes efficiently (31).

First, we packed the library into lentivirus with optimal titer at an MOI of 0.3 and transduced MV4-11 cells. After viral transduction, we treated the leukemia cells with 3 nmol/L AC220, an optimal dose chosen based on our preliminary tests (Fig. 1A). Transduction of MV4-11 with the CRISPR library but not the vector conferred resistance to AC220 in a subpopulation of cells (Fig. 1B). After 14 days of treatment, we harvested cells from the drug-treated group and extracted genomic DNA for PCR the region containing sgRNAs. Then, we conducted next-generation sequencing (deep sequencing) to identify sgRNAs enriched in drug-resistant cells (Fig. 1C). For a number of genes, we found enrichment of multiple sgRNAs that target a few genes after 14 days of AC220 treatment, suggesting that loss of these genes contributes to AC220 resistance (Fig. 1D). Then, we ranked the positive hits by the number of the sgRNAs and enrichment changes per sgRNA. As summarized in Supplementary Table S1, we identified one gene (*SPRY3*) with 6 sgRNAs and 12 genes with 5 sgRNAs/gene recovered. Our highest-ranking genes include *SPRY3*, *SERPINE1*, *NUAK1*, *NDUFS5*, *SULT1A3*, *HDAC5*, *DDRGK1*, and several members in proto cadherin alpha cluster. To further understand the pathways in AML cells conferring FLT3 inhibitor resistance, we also performed GO/GSEA/pathway analyses with our top candidates and found that genes regulating cell adhesion process are highly enriched (Supplementary Fig. S1). This result is consistent with the previous reports that components of the extracellular matrix and cell adhesion molecules can confer cell adhesion–mediated drug resistance to FLT3 inhibitors (34).

SPRY3 is a member of Sprouty proteins that has been shown to function as an antagonist of RTK-mediated Ras signaling. In addition, we also identified *GSK3* as a positive hit in our screen, and it has been well known to play an essential role in several signaling pathways in AML.

Knockouts of *SPRY3* and *GSK3* confer resistance to AC220

After identifying potential positive hits from our screen, we next validated whether loss of function of individual genes, *SPRY3* or *GSK3*, can cause drug resistance to AC220. *SPRY3* is our top candidate and the only gene with all 6 sgRNAs recovered in our screen. GSK3 has two isoforms GSK3α and GSK3β encoded by *GSK3A* and *GSK3B* genes. For *GSK3A* and *GSK3B*, we recovered four sgRNAs and two sgRNAs, respectively, in our screen. We chose *GSK3* because it has been implicated in several important downstream molecular pathways of FLT3, including Wnt and PI3K/Akt, in the pathogenesis of AML. To test whether deletion of *SPRY3* or *GSK3* confers resistance to AC220, we used five sgRNAs for *SPRY3* and two sgRNAs each for *GSK3A* and *GSK3B* to knock out *SPRY3* and *GSK3*, respectively, in the MV4-11 AML cell line. We transduced cells with lentivirus-carrying sgRNAs for the respective genes at an MOI of 20 and performed T7EN1 assays 5 days after transduction to determine the knockout efficiency. We found that the efficiency of gene disruption ranged from 30% to 90% for all sgRNAs tested (Fig. 2A).

To test whether deletion of *SPRY3* and *GSK3* can confer resistance to AC220, we infected MV4-11 with lentivirus-carrying sgRNA and treated transduced cells with different doses of AC220. We then measured cell viability at day 6 after treatment. Consistent with our screen data, *GSK3* or *SPRY3* knockout cells showed marked resistance to treatment with AC220 compared with the control cells (Fig. 2B). Importantly, in the absence of drug treatment, *SPRY3*- and *GSK3*-null cells grow as well as control cells (Fig. 2C).

Because the CRISPR/Cas9 system can create a spectrum of insertions/deletions (indels) in a cell population, we also tested drug resistance on cloned cells containing a single mutation. We transduced MV4-11 cells with sgRNA targeting *SPRY3* and performed a methylcellulose based colony-forming cell (CFC) assay. We then picked eight clones from the CFC assay, sequenced *SPRY3* in all eight clones, and found that six out of eight clones contained *SPRY3* mutations (Fig. 2D, top). We then used *SPRY3*$^{-/-}$ single-mutation clones to test the drug resistance to AC220. Consistent with the data from the heterogeneous population of CRISPR-mutated cells, all six *SPRY3* mutation clones showed strong

Published OnlineFirst June 16, 2017; DOI: 10.1158/0008-5472.CAN-16-1627



Figure 1.

CRISPR screen in MV4-11 AML cells uncovers genes whose loss of function confers AC220 resistance. **A,** Cell growth curve of MV4-11 following treatment with AC220. MV4-11 cells (0.3×10^6) were seeded in 12-well plate per well and cultured in complete medium supplemented with 1, 2, 3, 4, and 5 nmol/L AC220 or DMSO. Cell numbers were counted using Trypan blue at the indicated times. **B,** Cell growth curve of CRISPR GeCKO library transduced MV4-11 following the treatment of DMSO or AC220 over 14 days. Transduced cells (1×10^6) were seeded in 6-well plate per well and cultured in complete medium supplemented with 3 nmol/L AC220 or DMSO. Cell numbers were counted at indicated times. **C,** A simplified schematic of the AC220 resistance screen with MV4-11 AML cells. The screen condition has been tested for at least three times, and the transduction of AML cells and response to AC220 was very reproducible among three replicates. **D,** Enrichment of specific sgRNAs that target each gene after 14 days of AC220 treatment and identification of top candidate genes. The *x* axis represents enriched genes, and the *y* axis represents sgRNA enrichment score, which was calculated using (sgRNA number from the reads)/(sgRNA number in the library) $\times$ $\log_2$ (average abundance). The dotted line in the plot indicates the enrichment score for the nontargeting sgRNAs. The top 50 ranked genes based on the enrichment score are shown.

resistance to AC220 (Fig. 2D, bottom). The IC_{50} of 6 *SPRY3*-deleted clones was 2.69–5.39 nmol/L, whereas the IC_{50} for control cells was 0.7 nmol/L. Importantly, the deletion of *SPRY3* was confirmed by Western analysis. Furthermore, we also examined other Sprouty family members including *SPRY1*, *SPRY2*, and *SPRY4*, and found that their expression was not affected in *SPRY3* knockouts (Supplementary Fig. S2A and S2B). Crenolanib is another potent inhibitor of FLT3, and we also tested whether loss of *SPRY3* confers resistance to crenolanib. We observed that *SPRY3* knockout AML cells were resistant to crenolanib (Supplementary Fig. S2C). Notably, both *SPRY1* and *SPRY2* are highly expressed in AMLs. To address the question whether other Sprouty members also play a role in AC220 resistance, we designed sgRNAs targeting *SPRY1* and *SPRY2* to knock out these genes and tested AC220 resistance. Clearly, both *SPRY1* and *SPRY2* knockouts confer the resistance to AC220 in AML cells (Supplementary Fig. S2D).

SPRY3 knockout confers resistance to AC220 in primary AML cells

In order to confirm our findings in patients with AML, we measured *SPRY3* and *GSK3A* expression in 4 patients with AML who are treated with AC220 and clinically resistant to AC220 compared with 6 control AML patient samples who are *FLT3-ITD*$^+$ AML patients without AC220 treatment (Supplementary Table S2). Consistent with our data from the MV4-11 cell line, *SPRY3* and *GSK3A* expression was greatly reduced in AC220-resistant samples compared with the control samples (Fig. 3A). All four AC220-resistant samples were collected at progression to AC220 therapy in patients who previously responded clinically. Among these four AC220-resistant patient samples, we have pretreatment samples for three samples and measured the expression of *SPRY3* and *GSK3A* in these three-paired patient samples. Remarkably, we found that the expression of *SPRY3*

Published OnlineFirst June 16, 2017; DOI: 10.1158/0008-5472.CAN-16-1627



Figure 2.

Validation of the screen that disruption of *GSK3* and *SPRY3* in MV4-11 causes resistance to AC220. **A,** T7EN1 assay analysis of specific sgRNA-mediated indels at *GSK3* or *SPRY3* locus in MV4-11 cells. The MV4-11 cells were transduced with lentivirus carrying sgRNA-targeted *GSK3* or *SPRY3*. The genomic DNA from the cells was extracted and PCR amplified to test efficiency of gene disruptions by T7 endonuclease I assay using a 1.5% agarose gel. The lower migrating bands in lanes indicate the disrupted gene alleles. The left plot is *SPRY3*; middle plot is *GSK3A*; right plot is *GSK3B*. **B,** MV4-11 cells were transduced with lentivirus carrying sgRNAs targeting *GSK3* or *SPRY3*. The drug resistance of *GSK3* or *SPRY3* knockouts and the control cells were measured. Cells (0.4×10^6) were plated in 12-well plate and treated with indicated amounts of AC220 for 6 days, and cell numbers were counted. **C,** Cell growth curve of *SPRY3* and *GSK3* knockout cells in the absence of AC220. Cells (0.4×10^6) were plated in 12-well plate and cultured in complete medium. Cell numbers were counted at indicated times. The results from one representative experiment of three replicates are shown. **D,** Top, the sequence of mutant alleles in six *SPRY3* knockout single clones comparing with wild type on top. PAM sequence is labeled in gray. Bottom, cell growth curve of *SPRY3* knockout single clones following the treatment with AC220. Cells (0.4×10^6) were plated in 12-well plate and treated with indicated amounts of AC220 for 6 days and cell numbers were counted. The results from one representative experiment of three replicates are shown.

and *GSK3A* was dramatically reduced in the posttreatment samples compared with their baseline (Fig. 3B), suggesting that the expression of *SPRY3* and *GSK3A* might be correlated with the resistance to AC220 in patients. Furthermore, this is also an indication that the mutations identified by our CRISPR screen are clinically translatable.

To test the function of *SPRY3* in AC220 resistance in primary AML cells, we knocked out *SPRY3* in blasts from patients with

Published OnlineFirst June 16, 2017; DOI: 10.1158/0008-5472.CAN-16-1627



Figure 3.

Disruption of *SPRY3* in primary AML leads to resistance to AC220. **A,** Left, expression of *SPRY3* was measured by real-time PCR in control and AC220-resistant FLT3-ITD$^+$ AML patient samples. The expression level of *SPRY3* was normalized to housekeeping *PPIB* gene. Right, expression of *GSK3A* was measured by real-time PCR in control and AC220-resistant FLT3-ITD$^+$ AML patient samples. The expression level of *GSK3A* was normalized to housekeeping *PPIB* gene. **B,** Left, expression of *SPRY3* was measured by real-time PCR in three pairs of pre- and post-AC220 treatment FLT3-ITD$^+$ AML patient samples. The expression level of *SPRY3* was normalized to housekeeping *PPIB* gene. Right, expression of *GSK3A* was measured by real-time PCR in three pairs of pre- and post-AC220 treatment FLT3-ITD$^+$ AML patient samples. The expression level of *GSK3A* was normalized to housekeeping *PPIB* gene. **C,** T7EN1 assay analysis of specific sgRNA-mediated indels at *SPRY3* locus in the control and two FLT3-ITD$^+$ AML patient samples. **D,** *SPRY3* was deleted in FLT3-ITD$^+$ AML patient sample (#2) by transient transfection of Cas9 mRNA and a plasmid containing sgRNA. The resistance to AC220 was measured after 6 days of treatment. The results from one representative experiment of three replicates are shown.

FLT3-ITD$^+$ AML by transfecting Cas9 mRNA and a plasmid containing sgRNA. In blast from patient #2, we achieved approximately 50% targeting efficiency based on T7EN1 assay (Fig. 3C). Importantly, *SPRY3* deletion AML cells were resistant to AC220 compared with the parental primary AML cells (Fig. 3D). This result clearly demonstrated that loss of function of *SPRY3* results in AC220 resistance in primary AML cells. Taken together, *SPRY3* deletion in both an AML cell line and primary AML cells leads to drug resistance to a specific FLT3 inhibitor AC220.

SPRY3 or *GSK3* deletion/inhibition reactivates downstream signaling pathways of *FLT3-ITD* in the presence of AC220

In order to determine the mechanisms by which *SPRY3* or *GSK3* deletion confers drug resistance to AC220, we explored several different signaling pathways downstream of FLT3-ITD. *FLT3-ITD* mutation leads to constitutive activation of FLT3 kinase, with subsequent constitutive activation of its downstream signaling pathways including Ras/MAPK kinase pathway, STAT5, and PI3K/Akt pathway (9, 10). Moreover, it was also reported that cross-talk

Published OnlineFirst June 16, 2017; DOI: 10.1158/0008-5472.CAN-16-1627

between FLT3 and Wnt pathways plays a critical role in the pathogenesis of *FLT3-ITD*$^+$ AML (35, 36). As a potent and specific inhibitor of FLT3, AC220 can effectively inhibit all signaling downstream of FLT3. Because there is no wild-type control line for MV4-11, we used Ba/F3 as an alternative line to explore the pathways downstream of FLT3-ITD. Ba/F3 is an IL3-dependent murine pro–B-cell line, and stable expression of FLT3 in these cells allows IL3 to be substituted by FLT3 ligand. Consistent with previously published work, addition of FLT3 ligand augmented phosphorylation of AKT, ERK, and S6 and increased total levels of β-catenin, suggesting activation of PI3K/Akt, MAPK, mTOR, and Wnt pathways, respectively (Supplementary Fig. S3A). Moreover, expression of *FLT3-ITD* led to constitutive activation of AKT, ERK, and mTOR signaling (Supplementary Fig. S3A), indicating that the presence of *FLT3-ITD* in these cells enables ligand-independent activation of FLT3 downstream pathways.

Importantly, treating MV4-11 cells with AC220 for 2 hours reduced β-catenin levels as well as phosphorylation of STAT5, AKT, ERK, and S6 (Fig. 4A), suggesting inhibition of all downstream signaling pathways. To further confirm the effect of AC220 on



Figure 4.
AC220 inhibits multiple FLT3-ITD downstream signaling pathways, and knockouts of *SPRY3* or *GSK3* reactivate RAS/ERK and Wnt signaling pathways in the presence of AC220. **A,** Western blot analysis of AC220-treated MV4-11 cells. Cells (0.3×10^6) were starved for overnight and treated with AC220 at indicated concentrations. Cells were harvested after 2 hours of treatment and lysed. Then Western blot analysis was performed. The quantification of bands is shown below the gel. **B,** Western blot analysis of AC220-treated wild-type and *SPRY3* knockout cells. Note that 0.3×10^6 wild-type and *SPRY3* knockout cells were starved overnight and treated with 10 nmol/L AC220 for 6 hours. The cells were harvested and lysed, and Western blots analysis was carried out. **C,** Western blot analysis of AC220-treated wild-type and *GSK3* knockout cells. Cells (0.3×10^6) were starved overnight and treated with 10 nmol/L AC220. Cells were harvested at indicated times and lysed. Western blots analysis was performed.

Published OnlineFirst June 16, 2017; DOI: 10.1158/0008-5472.CAN-16-1627

FLT3-ITD signaling, we tested the effect of AC220 in BaF3 *FLT3-ITD*$^{+}$ cells as well. Similar to the data observed in MV4-11, we found that AC220 inhibits PI3K/Akt, MAPK, mTOR, and Wnt pathways that are all downstream pathways of FLT3-ITD (Supplementary Fig. S3B).

In terms of the mechanism of AC220 resistance, we speculated that gene mutations that can rescue signaling downstream of FLT3 kinase may confer resistance to AC220. As SPRY3 and GSK3 are known inhibitors of FGF/Ras/MAPK and Wnt signaling, respectively, we hypothesized that their loss of function (deletions) would restore Ras/MAPK and Wnt signaling downstream of FLT3 in the presence of AC220, thereby causing cells to be resistant to AC220. To test this hypothesis, we performed a series of experiments to probe for the signaling molecules that potentially regulate drug resistance due to *SPRY3* and *GSK3* disruptions. As we expected, *SPRY3* deletion led to increased phosphorylation of ERK in AC220-treated group compared with the wild type-control and specifically rescued the inhibition of RAS/MAPK signaling by AC220 in MV4-11 cells (Fig. 4B). *GSK3A* or *GSK3B* knockout also led to increased β-catenin in the presence of AC220, suggesting activation of Wnt signaling in the knockouts in the presence of AC220 (Fig. 4C).

Pharmacologic inhibition of MAP kinase and Wnt signaling pathway resensitizes AML cells to AC220

To further test our hypothesis that reactivation of the signaling downstream of FLT3-ITD is the mechanism underlying the resistance to AC220, we used a pharmacologic approach to modulate FGF signaling pathway. We treated MV4-11 cells with either FGF1 or FGF inhibitor PD161570 in combination with AC220. Consistent with our hypothesis, we observed that FGF1 treatment confers the cells resistant to AC220, whereas FGF inhibitor PD161570 sensitizes cells to AC220 (Fig. 5A). Biochemically, we



Figure 5.
Pharmacologic inhibition of MAP kinase and Wnt signaling pathway resensitizes AML cells to AC220. **A,** Growth curve of MV4-11 cells that were treated with 1 ng/mL FGFa or 50 nmol/L PD161570 or 1.5 μmol/L Chiron in combination with different doses of AC220. Cell numbers were counted after 3 days. **B,** Growth curve of MV4-11 or SPRY3 knockout MV4-11 cells that were treated with either DMSO or ERK inhibitor U0126 at 5 μmol/L in combination with different doses of AC220. Cell numbers were counted after 3 days. **C,** Growth curve of MV4-11 or GSK3A knockout MV4-11 cells that were treated with either DMSO or β-catenin inhibitor PNU74654 at 10 mmol/L in combination with different doses of AC220. Cell numbers were counted after 3 days.

Published OnlineFirst June 16, 2017; DOI: 10.1158/0008-5472.CAN-16-1627

observed that FGF1 treatment also increased phosphorylation of ERK (Supplementary Fig. S3C), suggesting FGF1 rescued the inhibition of MAPK signaling by AC220 in MV4-11.

To test whether activation of Wnt signaling can confer resistance to AC220, we treated MV4-11 FLT3-ITD$^+$ cells with a potent GSK3 inhibitor Chiron that activates Wnt signaling. We found that treatment of Chiron confers AML cells resistant to AC220. Biochemically, AC220 treatment reduced phosphorylation of AKT and ERK as well as the total protein levels of β-catenin in MV4-11. Addition of GSK3 inhibitor Chiron to AC220-treated cells increased total β-catenin levels without affecting other signaling pathways (Supplementary Fig. S3B and S3D), suggesting that GSK3 inhibition restores Wnt signaling in the presence of AC220.

To prove that MAP kinase is the major downstream effector of SPRY3 to confer resistance to AC220, we treated *SPRY3* KO with U0126, a highly selective inhibitor of both MEK1 and MEK2, and tested resistance to AC220. Supporting our hypothesis that MAP kinase is indeed the major downstream effector of the AC220 resistance pathway, we found that treatment of U0126 resensitizes AML cells to AC220 (Fig. 5B). Moreover, we also treated AML cells with a β-catenin inhibitor PNU74654 and found that it also resensitizes AML cells to AC220 (Fig. 5C). Together, these findings strongly suggest that reactivation of MAP kinase or Wnt signaling is the key mechanism to cause AC220 resistance in AML.

SPRY3 expression is downregulated in *GSK3* knockout AML cells

The similar resistance phenotype of *GSK3* and *SPRY3* knockouts suggests that these two genes might be functionally linked. To further understand the connection between *GSK3* and *SPRY3*, we measured the expression of *SPRY3* in *GSK3* knockout AML cells and *GSK3* expression in *SPRY3* knockout AML cells by real-time PCR. Interestingly, we found that *SPRY3* expression is markedly reduced in *GSK3* knockout cells (Fig. 6A). Conversely, expression of *GSK3* is not significantly altered in *SPRY3* knockout AML cells (Fig. 6B and C). Consistently, the protein level of SPRY3 was



Figure 6.

Expression of *SPRY3* is markedly reduced in *GSK3A* and *GSK3B* knockout AML cells. **A,** Expression of *SPRY3* was measured by real-time PCR in MV4-11, *SPRY3, GSK3A,* and *GSK3B* knockout MV4-11 cells. The expression level of *SPRY3* was normalized to housekeeping *PPIB* gene. **B,** Expression of *GSK3A* was measured by real-time PCR in MV4-11, *SPRY3, GSK3A,* and *GSK3B* knockout MV4-11 cells. The expression level of *GSK3A* was normalized to housekeeping *PPIB* gene. **C,** Expression of *GSK3B* was measured by real-time PCR in MV4-11, *SPRY3, GSK3A,* and *GSK3B* knockout MV4-11 cells. The expression level of *GSK3A* was normalized to housekeeping *PPIB* gene. **D,** The protein level of SPRY3 was assessed by Western blot in *GSK3A* and *GSK3B* knockout MV4-11 cells.

Published OnlineFirst June 16, 2017; DOI: 10.1158/0008-5472.CAN-16-1627

diminished in *GSK3* knockout AML cells (Fig. 6D). These data suggest that GSK3 might be the upstream regulator of SPRY3, and *GSK3* regulates transcription of *SPRY3* in the acquired AC220 resistance pathway.

Taken together, our results demonstrate that AC220 inhibits multiple pathways downstream of FLT3-ITD, whereas deletion of *SPRY3* or *GSK3* restores RAS/MAPK or Wnt signaling to confer resistance to AC220. *SPRY3* might be a downstream effector of *GSK3* in AC220 resistance signaling pathway.

No off-target mutagenesis was observed in *SPRY3* knockout

CRISPR/Cas9 has been demonstrated to create off-target mutations depending upon cell type and experimental setting (37, 38). To examine potential off-target effects, we predicted the possible off-target sites using an online tool (http://crispr.mit.edu) and identified at least six potential off-target sequences with high score for *SPRY3* sgRNA #4 (Supplementary Fig. S4A). Because there is only one predicted off-target sequence within a coding region (NM-001004439), we examined this site extensively. We PCR-amplified genomic DNA from primary AML cells and sequenced the PCR product of the potential off-target locus. When we scrutinized the sequencing data of four clones, we found that there are no mutations at this potential off-target site (Supplementary Fig. S4B). Although we cannot exclude the possibility of mutations at other sites, the off-target effects are unlikely given the phenotypes are observed with multiple sgRNAs.

Discussion

Pooled mutagenesis screen for gene mutations' mediating drug resistance

The CRISPR/Cas system, a powerful genome-editing approach, was initially discovered by several groups as an effective defense mechanism utilized by bacteria against virus infection (37–39). Subsequently, several seminal publications clearly demonstrated the possibility of using this technology to achieve high efficiency genome editing in mammalian systems, both mouse and human (40–42). Different versions of the guide RNA can be used to target Cas9 to specific sequences for genome engineering in cells as well as multicellular organisms (37, 39, 43). More recently, Dr. Feng Zhang's group at the Broad Institute of MIT and Harvard developed a CRISPR knockout library (GeCKO) and validated this system by performing a genome-wide screen for genes conferring drug resistance to a therapeutic BRAF inhibitor, Vemurafenib (PLX), in A375 melanoma cells. The screen revealed genes whose loss of function confers melanoma cells resistant to PLX (31). Of note, several other genome-wide CRISPR pooled screens have uncovered mediators of drug resistance, pathogen toxicity as well as defined cell-essential genes of the human genome (44–48). In our screen, for a number of genes, we found enrichment of multiple sgRNAs that target each gene after 14 days of AC220 treatment, suggesting that loss of these particular genes contributes to AC220 resistance. Thus, CRISPR has been proved to be a very useful tool to screen for drug-resistant mutants in several types of cancer cells including AML.

Downstream signaling molecules regulating drug resistance to FLT3 inhibitors

Given the importance of *FLT3* mutations in AML, TKIs have been developed to treat patients carrying *FLT3-ITD* mutations. Quizartinib (AC220), a more recent kinase inhibitor of FLT3, that has high selectivity for FLT3 is currently under clinical study. It has been shown to have very selective *in vitro* and *in vivo* activity and sensitivity against FLT3 (14, 49). In comparison with other FLT3 inhibitors, AC220 appears to be 1 to 2 orders of magnitude more potent *in vivo*. Moreover, it has a very long plasma half-life due to which it has improved pharmacokinetics. Interestingly, it has been reported that 11 of 45 patients (24%) receiving AC220 experienced transient clinical responses, and 4 patients achieved complete remission in a phase I study in relapsed/refractory AML (14, 49–51). Based on these promising phase I data, a phase II trial of AC220 in relapsed/refractory patients with *FLT3-ITD* mutations has been carried out. In this phase II study, as a monotherapy, AC220 at multiple doses demonstrated a high response rate in relapsed/refractory FLT3-ITD–positive patients. The treatment results in an overall better survival in FLT3-ITD–positive AML patients compared with historic survival data reported (14, 49–51).

Importantly, even though no FLT3 inhibitors have been approved for clinical use yet, several resistant mechanisms of FLT3 inhibitors have been reported through early clinical studies. Some studies identified the mutations in *FLT3* confer drug resistance (17, 52, 53). However, the drug-resistant mutations in the downstream pathways of FLT3 have not been systematically studied. Our study for the first time has uncovered that loss-of-functions of *SPRY3* and *GSK3* cause drug resistance. It also provides new insight into the signaling pathways downstream of FLT3-ITD in AML. Intriguingly, we found that expression of *SPRY3* is dramatically reduced in *GSK3* knockout AML cells. This result raises the possibility that *GSK3* regulates transcription of *SPRY3* directly or indirectly in acquired AC220 resistance pathway. It is tempting to speculate this regulation is through Wnt signaling. It would be important to explore the detailed mechanism by which *GSK3* controls transcription of *SPRY3* in AML cells.

Relevance of identified drug-resistant mutations to human leukemia

In our screen, we identified *SPRY3* and *GSK3* as positive hits, and loss of function of *SPRY3* or *GSK3* leads to the resistance of AML cells to AC220. Importantly, we confirmed this resistance effect in primary leukemia samples. Furthermore, we also demonstrated that the expression level of *SPRY3* and *GSK3A* correlates with clinical AC220 resistance in human leukemia samples. All these data strongly suggest that the genes we identified in our screen play a critical role in AC220 resistance in primary human AML samples. Importantly, we also showed that treating cells with either FGF signaling inhibitor or MAPK inhibitor or β-catenin inhibitor greatly increases the sensitivity of AML cells to AC220. This could be potentially important for developing future FLT3-ITD$^+$ AML synergistic anti-AML therapy. It would be interesting to test whether treating patients who are clinically resistant to AC220 with FGF inhibitor or MAPK inhibitor would resensitize leukemic cells to AC220. Of note, our conclusion is also further supported by a recent report showing that FGF2 promoted resistance to AC220 through activation of FGFR1 and downstream MAPK effectors in AML cells (54). In summary, our study identified and delineated novel functional roles for *SPRY3* and *GSK3* genes whose deletions lead to FLT3 inhibitor resistance and provided new

Published OnlineFirst June 16, 2017; DOI: 10.1158/0008-5472.CAN-16-1627



Figure 7.

Model of *SPRY3* or *GSK3* knockouts confers resistance to AC220. FLT3-ITD constitutively activates downstream signaling pathways of FLT3. Treatment of FLT3-ITD$^+$ cells with AC220 inhibits all the pathways. *SPRY3* or *GSK3* knockouts reactivate downstream signaling pathways of FLT3-ITD and confer resistance to AC220. The untreated or AC220-sensitive AML cells can develop drug resistance during the therapy because of *SPRY3* or *GSK3* mutations. The major downstream signaling pathways are Wnt and MAP kinase pathways.

insights into the downstream signaling pathways regulated by FLT3 (Fig. 7).

Disclosure of Potential Conflicts of Interest

A. Perl is a consultant/advisory board member for Arog, Astellas, Daiichi Sankyo, Novartis, and Takeda. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: P. Hou, C.D. Santos, J. Huang
Development of methodology: P. Hou, C. Wu, C.D. Santos, D. Guo
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): P. Hou, C. Wu, Y. Yang, R. Qi, H. Zheng, A. Perl
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): P. Hou, C. Wu, Y. Wang, Z. Zuo, H. Wang, J. Huang
Writing, review, and/or revision of the manuscript: P. Hou, C. Wu, Y. Yang, D. Bhavanasi, C.D. Santos, Y. Chen, H. Zheng, H. Wang, A. Perl, D. Guo, J. Huang
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): C. Wu, S. Chen, Y. Chen, H. Wang
Study supervision: D. Guo, J. Huang

Acknowledgments

We thank Dr. Martin Carroll, Peter Klein at University of Pennsylvania, and Drs. Yuri Persidsky, Jean-Pierre Issa, and Yi Zhang at Temple University School of Medicine for their insightful comments and discussion. We specially thank Dr. Hong Tian for technical support to our study. We thank all the members of Klein lab for their help and discussions. We thank the Stem cell and Xenograft core facility of UPenn for providing us with the AML samples, especially Dr. Gwenn Danet-Desnoyers. We greatly thank Dr. Yuesheng Li from Genomic facility of Fox Chase Cancer Center for help with the deep sequencing. We specially thank Xiang Yu at University of Pennsylvania and Tian Tian at New Jersey Institute of Technology for assistance of bioinformatic analysis.

Grant Support

J. Huang has been awarded a grant from the NHLBI (R00 HL107747-04) and seed grant from Temple University Lewis Katz School of Medicine.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 14, 2016; revised October 29, 2016; accepted June 12, 2017; published OnlineFirst June 16, 2017.

References

1. Parcells BW, Ikeda AK, Simms-Waldrip T, Moore TB, Sakamoto KM. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells 2006;24:1174–84.
2. Naoe T, Kiyoi H. Normal and oncogenic FLT3. Cell Mol Life Sci 2004;61:2932–8.
3. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532–42.
4. Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia 2003;17:1738–52.
5. Estey EH.Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 2013;88:318–27.
6. Konig H, Levis M. Targeting FLT3 to treat leukemia. Expert Opin Ther Targets 2015;19:37–54.
7. Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 2012;26:2176–85.
8. Perl AE, Carroll M. Exploiting signal transduction pathways in acute myelogenous leukemia. Curr Treat Options Oncol 2007;8:265–76.
9. Takahashi S.Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol 2011;4:13.
10. Grafone T, Palmisano M, Nicci C, Storti S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev 2012;6:e8.
11. Gilliland DG.FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors. Best Pract Res Clin Haematol 2003;16:409–17.
12. Small D.Targeting FLT3 for the treatment of leukemia. Semin Hematol 2008;45:S17–21.
13. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003;3:650–65.
14. Fathi A, Levis M. FLT3 inhibitors: a story of the old and the new. Curr Opin Hematol 2011;18:71–6.
15. Scott E, Hexner E, Perl A, Carroll M. Targeted signal transduction therapies in myeloid malignancies. Curr Oncol Rep 2010;12:358–65.
16. Smith CC, Shah NP. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Am Soc Clin Oncol Educ Book 2013:313–8.
17. Wander SA, Levis MJ, Fathi AT. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol 2014;5:65–77.
18. Guy GR, Jackson RA, Yusoff P, Chow SY. Sprouty proteins: modified modulators, matchmakers or missing links? J Endocrinol 2009;203:191–202.
19. Kim HJ, Bar-Sagi D. Modulation of signalling by Sprouty: a developing story. Nat Rev Mol Cell Biol 2004;5:441–50.
20. Edwin F, Anderson K, Ying C, Patel TB. Intermolecular interactions of Sprouty proteins and their implications in development and disease. Mol Pharmacol 2009;76:679–91.
21. Felfly H, Klein OD. Sprouty genes regulate proliferation and survival of human embryonic stem cells. Sci Rep 2013;3:2277.
22. Edwin F, Singh R, Endersby R, Baker SJ, Patel TB. The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. J Biol Chem 2006;281:4816–22.
23. Holgren C, Dougherty U, Edwin F, Cerasi D, Taylor I, Fichera A, et al. Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. Oncogene 2010;29:5241–53.
24. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003;116:1175–86.
25. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001;359:1–16.
26. Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VM, Klein PS. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol 1997;185:82–91.
27. Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE, Gottesman MM. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat 2012;15:62–9.
28. Estey EH.Acute myeloid leukemia: 2014 update on risk-stratification and management. Am J Hematol 2014;89:1063–81.
29. Weisberg E, Choi HG, Barrett R, Zhou W, Zhang J, Ray A, et al. Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol Cancer Ther 2010;9:2468–77.
30. Sudhindra A, Smith CC. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014;9:174–85.
31. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014;343:84–7.
32. Hou P, Chen S, Wang S, Yu X, Chen Y, Jiang M, et al. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep 2015;5:15577.
33. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 2003;17:120–4.
34. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010;116:5089–102.
35. Jiang J, Griffin JD. Wnt/beta-catenin pathway modulates the sensitivity of the mutant FLT3 receptor kinase inhibitors in a GSK-3beta dependent manner. Genes Cancer 2010;1:164–76.
36. Tickenbrock L, Schwable J, Wiedehage M, Steffen B, Sargin B, Choudhary C, et al. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood 2005;105:3699–706.
37. Wright AV, Nunez JK, Doudna JA. Biology and Applications of CRISPR systems: harnessing nature's toolbox for genome engineering. Cell 2016;164:29–44.
38. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 2014;32:347–55.
39. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014;157:1262–78.
40. Marraffini LA.CRISPR-Cas immunity in prokaryotes. Nature 2015;526:55–61.
41. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339:819–23.
42. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science 2013;339:823–6.
43. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014;346:1258096.
44. Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, et al. Identification and characterization of essential genes in the human genome. Science 2015;350:1096–101.
45. Ma H, Dang Y, Wu Y, Jia G, Anaya E, Zhang J, et al. A CRISPR-based screen identifies genes essential for west-nile-virus-induced cell death. Cell Rep 2015;12:673–83.
46. Parnas O, Jovanovic M, Eisenhaure TM, Herbst RH, Dixit A, Ye CJ, et al. A genome-wide CRISPR screen in primary immune cells to dissect regulatory networks. Cell 2015;162:675–86.
47. Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol 2015;33:661–7.
48. Chen S, Sanjana NE, Zheng K, Shalem O, Lee K, Shi X, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 2015;160:1246–60.
49. Kiyoi H.Flt3 inhibitors: recent advances and problems for clinical application. Nagoya J Med Sci 2015;77:7–17.
50. Engen CB, Wergeland L, Skavland J, Gjertsen BT. Targeted therapy of FLT3 in treatment of AML-current status and future directions. J Clin Med 2014;3:1466–89.
51. Fathi AT, Chen YB. Treatment of FLT3-ITD acute myeloid leukemia. Am J Blood Res 2011;1:175–89.
52. Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 2009;12:81–9.
53. Williams AB, Nguyen B, Li L, Brown P, Levis M, Leahy D, et al. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013;27:48–55.
54. Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, et al. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia. Cancer Res 2016;76:6471–82.

Cancer Research
The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

AACR American Association for Cancer Research

A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220

Panpan Hou, Chao Wu, Yuchen Wang, et al.

Cancer Res 2017;77:4402-4413. Published OnlineFirst June 16, 2017.